CoChat
Sign Up
Cited by 5

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Nanocarrier-based targeted pulmonary delivery: novel approaches for effective lung cancer treatment

Shah, Muhammad Raza, Imran, Muhammad, Ullah, Shafi·2019·Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy
DOI 10.1016/b978-0-12-816773-1.00006-7
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/b978-0-12-816773-1.00006-7

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 141

  1. Abdelaziz, 2018, Inhalable particulate drug delivery systems for lung cancer therapy: nanoparticles, microparticles, nanocomposites and nanoaggregates, J. Control. Release., 269, 374, 10.1016/j.jconrel.2017.11.036 · DOI
  2. Abu-Dahab, 2001, Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion, Eur. J. Pharm. Sci., 14, 37, 10.1016/S0928-0987(01)00147-6 · DOI
  3. Ahmad, 2015, Nanotechnology-based inhalation treatments for lung cancer: state of the art, Nanotechnol. Sci. Appl., 8, 55
  4. Ahn, 2014, A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer, Cancer Chemother. Pharmacol., 74, 277, 10.1007/s00280-014-2498-5 · DOI
  5. Anabousi, 2006, In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer, Eur. J. Pharm. Sci., 29, 367, 10.1016/j.ejps.2006.07.004 · DOI
  6. Anabousi, 2006, Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant, J. Nanosci. Nanotechnol., 6, 3010, 10.1166/jnn.2006.461 · DOI
  7. Anderson, 2006, Use of Respimat® soft Mist™ inhaler in COPD patients, Int. J. Chron. Obstruct. Pulmon. Dis., 1, 251
  8. Arriagada, 1985, Alternating radiotherapy and chemotherapy schedules in small cell lung cancer, limited disease, Int. J. Radiat. Oncol. Biol. Phys., 11, 1461, 10.1016/0360-3016(85)90333-5 · DOI
  9. Bae, 2005, Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery, Mol. Biosyst., 1, 242, 10.1039/b500266d · DOI
  10. Bae, 2013, Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging, Adv. Healthc. Mater., 2, 576, 10.1002/adhm.201200338 · DOI
  11. Bangham, 1965, Diffusion of univalent ions across the lamellae of swollen phospholipids, J. Mol. Biol., 13, 238, 10.1016/S0022-2836(65)80093-6 · DOI · Paper page
  12. Beisner, 2009, Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2′-O-methyl-RNA, J. Pharm. Sci., 98, 1765, 10.1002/jps.21553 · DOI
  13. Blanco, 2009, Multifunctional micellar nanomedicine for cancer therapy, Exp. Biol. Med., 234, 123, 10.3181/0808-MR-250 · DOI
  14. Bulbake, 2017, Liposomal formulations in clinical use: an updated review, Pharmaceutics, 9, 12, 10.3390/pharmaceutics9020012 · DOI
  15. Byrne, 2008, Active targeting schemes for nanoparticle systems in cancer therapeutics, Adv. Drug Deliv. Rev., 60, 1615, 10.1016/j.addr.2008.08.005 · DOI
  16. Chen, 2007, Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model, Mol. Pharm., 4, 713, 10.1021/mp060132k · DOI
  17. Courrier, 2002, Pulmonary drug delivery systems: recent developments and prospects, Crit. Rev. Therap. Drug Carrier Syst., 19, 425, 10.1615/CritRevTherDrugCarrierSyst.v19.i45.40 · DOI
  18. Davis, 2010, Nanoparticle therapeutics: an emerging treatment modality for cancer, Nanosci. Technol., 239
  19. De Jong, 2008, Drug delivery and nanoparticles: applications and hazards, Int. J. Nanomed., 3, 133, 10.2147/IJN.S596 · DOI
  20. Delaney, 2005, The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines, Cancer: Interdiscip. Int. J. Am. Cancer Soc., 104, 1129, 10.1002/cncr.21324 · DOI
  21. Devarajan, 2004, Low renal toxicity of lipoplatin compared to cisplatin in animals, Anticancer Res., 24, 2193
  22. Didkowska, 2016, Lung cancer epidemiology: contemporary and future challenges worldwide, Ann. Transl. Med., 4, 150, 10.21037/atm.2016.03.11 · DOI
  23. Dolmans, 2003, Photodynamic therapy for cancer, Nat. Rev. Cancer, 3, 380, 10.1038/nrc1071 · DOI
  24. Dolovich, 2011, Aerosol drug delivery: developments in device design and clinical use, Lancet, 377, 1032, 10.1016/S0140-6736(10)60926-9 · DOI
  25. Duggan, 2011, Pegylated liposomal doxorubicin, Drugs, 71, 2531, 10.2165/11207510-000000000-00000 · DOI · Paper page
  26. Ellerhorst, 1999, Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy, Oncol. Rep., 6, 1097
  27. El-Readi, 2010, Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines, Eur. J. Pharmacol., 626, 139, 10.1016/j.ejphar.2009.09.040 · DOI
  28. Eytan, 1999, Mechanism of action of P-glycoprotein in relation to passive membrane permeation, 10.1016/S0074-7696(08)62148-8 · DOI
  29. Fang, 2011, The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect, Adv. Drug Deliv. Rev., 63, 136, 10.1016/j.addr.2010.04.009 · DOI
  30. Farokhzad, 2006, Nanomedicine: developing smarter therapeutic and diagnostic modalities, Adv. Drug Deliv. Rev., 58, 1456, 10.1016/j.addr.2006.09.011 · DOI
  31. Fassas, 2005, The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia, Leuk. Lymphoma, 46, 795, 10.1080/10428190500052438 · DOI
  32. Ferrari, 2005, Cancer nanotechnology: opportunities and challenges, Nat. Rev. Cancer, 5, 161, 10.1038/nrc1566 · DOI · Paper page
  33. Fried, 2004, Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer, J. Clin. Oncol., 22, 4837, 10.1200/JCO.2004.01.178 · DOI
  34. Ganesh, 2007, Improved biochemical strategies for targeted delivery of taxoids, Bioorg. Med. Chem., 15, 3597, 10.1016/j.bmc.2007.03.041 · DOI
  35. Gehr, 1996, Airway surfactant, a primary defense barrier: mechanical and immunological aspects, J. Aerosol Med., 9, 163, 10.1089/jam.1996.9.163 · DOI
  36. Gennatas, 2015, Patterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centres, BMJ Open, 5, e006440, 10.1136/bmjopen-2014-006440 · DOI
  37. Goel, 2013, Exploring targeted pulmonary delivery for treatment of lung cancer, Int. J. Pharm. Investig., 3, 8, 10.4103/2230-973X.108959 · DOI
  38. Goerke, 1998, Pulmonary surfactant: functions and molecular composition, Biochim. Biophys. Acta (BBA)—Mol. Basis Dis., 1408, 79, 10.1016/S0925-4439(98)00060-X · DOI
  39. Greco, 2009, Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines, Adv. Drug Deliv. Rev., 61, 1203, 10.1016/j.addr.2009.05.006 · DOI
  40. Green, 2006, Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer, Ann. Oncol., 17, 1263, 10.1093/annonc/mdl104 · DOI
  41. Groneberg, 2003, Fundamentals of pulmonary drug delivery, Respir. Med., 97, 382, 10.1053/rmed.2002.1457 · DOI
  42. Gupta, 2012, Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy, Antioxid. Redox. Signal., 16, 1295, 10.1089/ars.2011.4414 · DOI
  43. Haag, 2006, Polymer therapeutics: concepts and applications, Angew. Chem. Int. Ed., 45, 1198, 10.1002/anie.200502113 · DOI
  44. Haitsma, 2001, Exogenous surfactant as a drug delivery agent, Adv. Drug Deliv. Rev., 47, 197, 10.1016/S0169-409X(01)00106-5 · DOI
  45. Hidalgo, 2015, Barrier or carrier? Pulmonary surfactant and drug delivery, Eur. J. Pharm. Biopharm., 95, 117, 10.1016/j.ejpb.2015.02.014 · DOI
  46. Hirsjarvi, 2011, Passive and active tumour targeting with nanocarriers, Curr. Drug Discov. Technol., 8, 188, 10.2174/157016311796798991 · DOI
  47. Hitzman, 2006, Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles, J. Pharm. Sci., 95, 1114, 10.1002/jps.20591 · DOI
  48. Hiyama, 1995, Telomerase activity in small-cell and non–small-cell lung cancers, JNCI: J. Natl. Cancer Inst., 87, 895, 10.1093/jnci/87.12.895 · DOI
  49. Hoet, 2004, Nanoparticles–known and unknown health risks, J. Nanobiotechnol., 2, 12, 10.1186/1477-3155-2-12 · DOI
  50. Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599 · DOI · Paper page
  51. Hu, 2012, Nanoparticle-based combination therapy toward overcoming drug resistance in cancer, Biochem. Pharmacol., 83, 1104, 10.1016/j.bcp.2012.01.008 · DOI
  52. Hu, 2013, Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial), Trials, 14, 45, 10.1186/1745-6215-14-45 · DOI
  53. In, 2015, Emerging chemotherapy agents in lung cancer: nanoparticles therapeutics for non-small cell lung cancer, Transl. Cancer Res., 4, 340
  54. Jabir, 2012, Nanotechnology-based approaches in anticancer research, Int. J. Nanomed., 7, 4391
  55. Jabr-Milane, 2008, Multi-functional nanocarriers for targeted delivery of drugs and genes, J. Control. Release, 130, 121, 10.1016/j.jconrel.2008.04.016 · DOI
  56. Jain, 2012, Gold nanoparticles as novel agents for cancer therapy, Br. J. Radiol., 85, 101, 10.1259/bjr/59448833 · DOI
  57. Jiang, 2013, Thiolated chitosan-modified PLA-PCL-TPGS nanoparticles for oral chemotherapy of lung cancer, Nanoscale Res. Lett., 8, 66, 10.1186/1556-276X-8-66 · DOI
  58. Johansson, 1994, The proteins of the surfactant system, Eur. Respir. J., 7, 372, 10.1183/09031936.94.07020372 · DOI
  59. Jung, 2012, Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer, Int. J. Radiat. Oncol. Biol. Phys., 84, e77, 10.1016/j.ijrobp.2012.02.030 · DOI
  60. Kaminskas, 2014, Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy, J. Control. Release, 183, 18, 10.1016/j.jconrel.2014.03.012 · DOI
  61. Karra, 2013, Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model, Small, 9, 4221, 10.1002/smll.201301417 · DOI
  62. Kelland, 2007, The resurgence of platinum-based cancer chemotherapy, Nat. Rev. Cancer, 7, 573, 10.1038/nrc2167 · DOI
  63. Khan, 2018, In vitro and in vivo antitumor potential of carvacrol nanoemulsion against human lung adenocarcinoma A549 cells via mitochondrial mediated apoptosis, Sci. Rep., 8, 144, 10.1038/s41598-017-18644-9 · DOI
  64. Kim, 2004, Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies, Clin. Cancer Res., 10, 3708, 10.1158/1078-0432.CCR-03-0655 · DOI · Paper page
  65. Koudelka, 2012, Liposomal paclitaxel formulations, J. Control. Release, 163, 322, 10.1016/j.jconrel.2012.09.006 · DOI
  66. Koul, 2012, Surgery in limited-disease small-cell lung cancer, Lung India, 29, 2, 10.4103/0970-2113.92345 · DOI
  67. Kumar, 2004, Preparation and characterization of cationic PLGA nanospheres as DNA carriers, Biomaterials., 25, 1771, 10.1016/j.biomaterials.2003.08.069 · DOI
  68. Lam, 1994, Photodynamic therapy of lung cancer, Semin. Oncol., 15
  69. Landesman-Milo, 2015, Nanomedicine as an emerging platform for metastatic lung cancer therapy, Cancer Metastasis Rev., 34, 291, 10.1007/s10555-015-9554-4 · DOI
  70. Larina, 2005, Enhancement of drug delivery in tumors by using interaction of nanoparticles with ultrasound radiation, Technol. Cancer Res. Treat., 4, 217, 10.1177/153303460500400211 · DOI
  71. Lavan, 2003, Small-scale systems for in vivo drug delivery, Nat. Biotechnol., 21, 1184, 10.1038/nbt876 · DOI
  72. Lee, 2008, Synthesis and characterization of positive-charge functionalized mesoporous silica nanoparticles for oral drug delivery of an anti-inflammatory drug, Adv. Funct. Mater., 18, 3283, 10.1002/adfm.200800521 · DOI
  73. Lee, 2009, Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment, Blood, 114, 589, 10.1182/blood-2009-02-206870 · DOI · Paper page
  74. Lee, 2014, Recent advances in curcumin nanoformulation for cancer therapy, Expert Opin. Drug Deliv., 11, 1183, 10.1517/17425247.2014.916686 · DOI
  75. Lee, 2015, Inhalation of nanoparticle-based drug for lung cancer treatment: advantages and challenges, Asian J. Pharm. Sci., 10, 481, 10.1016/j.ajps.2015.08.009 · DOI
  76. Lee, 2016, Nanoparticle-based targeted gene therapy for lung cancer, Am. J. Cancer Res., 6, 1118
  77. Liu, 2011, Novel peptide–dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer, Int. J. Nanomed., 6, 59
  78. Liu, 2011, Paclitaxel-loaded expansile nanoparticles delay local recurrence in a heterotopic murine non-small cell lung cancer model, Ann. Thorac. Surg., 91, 1077, 10.1016/j.athoracsur.2010.12.040 · DOI
  79. Liu, 2014, Effects of internalized gold nanoparticles with respect to cytotoxicity and invasion activity in lung cancer cells, PLoS One, 9, e99175, 10.1371/journal.pone.0099175 · DOI
  80. Longo, D.L., 1998. Approach to the patient with cancer. In: Harrisons Principles of Internal Medicine, pp. 493–498, McGraw-Hill edication, New York City, New York, United States.
  81. Love, 1989, Side effects and emotional distress during cancer chemotherapy, Cancer, 63, 604, 10.1002/1097-0142(19890201)63:3<604::AID-CNCR2820630334>3.0.CO;2-2 · DOI
  82. Lu, 2013, Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs, Int. J. Pharm., 453, 198, 10.1016/j.ijpharm.2012.08.042 · DOI · Paper page
  83. Ma, 2016, Future of nanotherapeutics: targeting the cellular sub-organelles, Biomaterials, 97, 10, 10.1016/j.biomaterials.2016.04.026 · DOI
  84. Madni, 2017, Novel nanoparticulate systems for lung cancer therapy: an updated review, J. Drug Target., 25, 499, 10.1080/1061186X.2017.1289540 · DOI
  85. Maeda, 1989, Tumoritropic and lymphotropic principles of macromolecular drugs, Crit. Rev. Ther. Drug Carrier Syst., 6, 193
  86. Mahajan, 2014, Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting, Drug Deliv., 21, 148, 10.3109/10717544.2013.838014 · DOI · Paper page
  87. Mansour, 2003, A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2, Cancer Res., 63, 4062
  88. Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 46, 6387
  89. Mattern, 1995, Vascular endothelial growth-factor expression and angiogenesis in nonsmall cell lung carcinomas, Int. J. Oncol., 6, 1059
  90. McClements, 2011, Food-grade nanoemulsions: formulation, fabrication, properties, performance, biological fate, and potential toxicity, Crit. Rev. Food Sci. Nutr., 51, 285, 10.1080/10408398.2011.559558 · DOI
  91. Messerschmidt, 2009, Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells, J. Control. Release, 137, 69, 10.1016/j.jconrel.2009.03.010 · DOI
  92. Morgan, 2006, Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro, Cancer Res., 66, 11913, 10.1158/0008-5472.CAN-06-2066 · DOI
  93. Nafee, 2007, Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides, Nanomed.: Nanotechnol. Biol. Med., 3, 173, 10.1016/j.nano.2007.03.006 · DOI
  94. Nishiyama, 2003, Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice, Cancer Res., 63, 8977
  95. Patton, 1996, Mechanisms of macromolecule absorption by the lungs, Adv. Drug Deliv. Rev., 19, 3, 10.1016/0169-409X(95)00113-L · DOI
  96. Patton, 2007, Inhaling medicines: delivering drugs to the body through the lungs, Nat. Rev. Drug Discov., 6, 67, 10.1038/nrd2153 · DOI
  97. Peng, 2008, Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy, Int. J. Nanomed., 3, 311
  98. Perkins, W., Weers, J., Meers, P., 2005. An inhalation formulation of liposomal cisplatin (SLIT2 cisplatin) for treatment of lung cancer. In: Conference Vancouver, pp. 26–30.
  99. Pignon, 1992, A meta-analysis of thoracic radiotherapy for small-cell lung cancer, N. Engl. J. Med., 327, 1618, 10.1056/NEJM199212033272302 · DOI
  100. Polito, 1998, Epithelial cells as regulators of airway inflammation, J. Allergy Clin. Immunol., 102, 714, 10.1016/S0091-6749(98)70008-9 · DOI
  101. Powell, 2006, Nanomaterial health effects-Part 2: Uncertainties and recommendations for the future, Wis. Med. J., 105, 18
  102. Ramalingam, 2008, Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions, Oncologist, 13, 5, 10.1634/theoncologist.13-S1-5 · DOI
  103. Ramalingam, 2011, Lung cancer: new biological insights and recent therapeutic advances, CA Cancer J. Clin., 61, 91, 10.3322/caac.20102 · DOI
  104. Rani, 2012, Advances in cancer nanomedicine, J. Indian Inst. Sci., 92, 187
  105. Respaud, 2015, Nebulization as a delivery method for mAbs in respiratory diseases, Expert. Opin. Drug Deliv., 12, 1027, 10.1517/17425247.2015.999039 · DOI
  106. Reynolds, 2009, Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer, J. Thor. Oncol., 4, 1537, 10.1097/JTO.0b013e3181c0a2f4 · DOI
  107. Rodriguez, 2010, Small cell lung cancer: past, present, and future, Curr. Oncol. Rep., 12, 327, 10.1007/s11912-010-0120-5 · DOI
  108. Sacerdote, 2000, The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients, Anesthesia Analgesia, 90, 1411, 10.1097/00000539-200006000-00028 · DOI
  109. Sanna, 2014, Targeted therapy using nanotechnology: focus on cancer, Int. J. Nanomed., 9, 467
  110. Senan, 2004, Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer, Radiother. Oncol., 71, 139, 10.1016/j.radonc.2003.09.007 · DOI
  111. Shah, 2012, Pulmonary drug delivery: a promising approach, J. Appl. Pharm. Sci., 2, 33
  112. Shay, 2006, Telomerase therapeutics for cancer: challenges and new directions, Nat. Rev. Drug Discov., 5, 577, 10.1038/nrd2081 · DOI
  113. Shishu, 2009, Dendrimers: the novel pharmaceutical drug carriers, IJPSR, 2, 493
  114. Siegel, 2011, Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths, CA Cancer J. Clin., 61, 212, 10.3322/caac.20121 · DOI
  115. Siegel, 2017, Cancer statistics, 2018 CA: a cancer, J. Clin., 68, 7
  116. Spencer, 1964, Morphometry of the human lung, J. Anat., 98, 457
  117. Spratlin, 2007, Pharmacogenetics of paclitaxel metabolism, Crit. Rev. Oncol. Hematol., 61, 222, 10.1016/j.critrevonc.2006.09.006 · DOI
  118. Stathopoulos, 2012, Lipoplatin formulation review article, J. Drug Deliv., 2012, 10.1155/2012/581363 · DOI · Paper page
  119. Steichen, 2013, A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics, Eur. J. Pharm. Sci., 48, 416, 10.1016/j.ejps.2012.12.006 · DOI · Paper page
  120. Stone, 1992, Allometric relationships of cell numbers and size in the mammalian lung, Am. J. Respir. Cell Mol. Biol., 6, 235, 10.1165/ajrcmb/6.2.235 · DOI
  121. Su, 2014, Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy, Cancer Biol. Med., 11, 86
  122. Sung, 2007, Nanoparticles for drug delivery to the lungs, Trends Biotechnol., 25, 563, 10.1016/j.tibtech.2007.09.005 · DOI
  123. Taetz, 2009, The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2′-O-methyl-RNA directed against telomerase in lung cancer cells, Eur. J. Pharm. Biopharm., 72, 358, 10.1016/j.ejpb.2008.07.011 · DOI
  124. Taratula, 2011, Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA, J. Drug Target., 19, 900, 10.3109/1061186X.2011.622404 · DOI
  125. Tiwari, 2006, Preparation and in vitro characterization of multifunctional nanoemulsions for simultaneous MR imaging and targeted drug delivery, J. Biomed. Nanotechnol., 2, 217, 10.1166/jbn.2006.038 · DOI
  126. Torchilin, 2005, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov., 4, 145, 10.1038/nrd1632 · DOI · Paper page
  127. Tseng, 2007, Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting, Biomaterials, 28, 3996, 10.1016/j.biomaterials.2007.05.006 · DOI
  128. Verma, 2016, Perspectives of nanoemulsion assisted oral delivery of docetaxel for improved chemotherapy of cancer, Drug Deliv., 23, 479, 10.3109/10717544.2014.920430 · DOI
  129. Vermehren, 2006, Lung surfactant as a drug delivery system, Int. J. Pharm., 307, 89, 10.1016/j.ijpharm.2005.10.029 · DOI
  130. Wang, 2001, Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging, Eur. Radiol., 11, 2319, 10.1007/s003300100908 · DOI · Paper page
  131. Wang, 2010, ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation, Nanomedicine, 5, 361, 10.2217/nnm.10.6 · DOI
  132. Warde, 1992, Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis, J. Clin. Oncol., 10, 890, 10.1200/JCO.1992.10.6.890 · DOI
  133. Whitesides, 2003, The ‘right’ size in nanobiotechnology, Nat. Biotechnol., 21, 1161, 10.1038/nbt872 · DOI
  134. Wittgen, 2007, Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung, Clin. Cancer Res., 13, 2414, 10.1158/1078-0432.CCR-06-1480 · DOI
  135. Wozniak, 1998, Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study, J. Clin. Oncol., 16, 2459, 10.1200/JCO.1998.16.7.2459 · DOI
  136. Wu, 2008, Multifunctional mesoporous silica nanoparticles for intracellular labeling and animal magnetic resonance imaging studies, Chembiochem, 9, 53, 10.1002/cbic.200700509 · DOI
  137. Xie, 2010, Pulmonary delivery of cisplatin–hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer, Int. J. Pharm., 392, 156, 10.1016/j.ijpharm.2010.03.058 · DOI
  138. Yan, 2009, Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer, J. Clin. Oncol., 27, 2553, 10.1200/JCO.2008.18.2733 · DOI
  139. Yano, 2014, Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer, World J. Clin. Oncol., 5, 1048, 10.5306/wjco.v5.i5.1048 · DOI
  140. Zarogoulidis, 2012, Inhaled chemotherapy in lung cancer: future concept of nanomedicine, Int. J. Nanomed., 7, 1551, 10.2147/IJN.S29997 · DOI
  141. Zinkl, J.G., 2001. Lower respiratory tract. In: Schrefer, J.A. (Ed.), Diagnostic Cytology and Hematology of the Horse, second ed., pp. 73–86, Elsevier, Amsterdam, Netherlands. · DOI

Cited by

Sorted by citations

Metadata

Authors
Shah, M. R., Imran, M., & Ullah, S.
Venue
Nanocarriers for Cancer Diagnosis and Targeted Chemotherapy
Publisher
Elsevier
Published
2019
Pages
129-161
DOI
10.1016/b978-0-12-816773-1.00006-7
Cited by
5
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review